| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men and women |
| Source | Honolulu Star-Advertiser (Reuters) |
| URL | staradvertiser.com/2026/09/19/hawaii-news/pentagon-revives-testosterone-testing-after-pause-excludes-women (opens in a new tab) |
Specific Claim Evaluated
The FDA removed the boxed warning on cardiovascular risk last year and in June asked manufacturers to remove the limitation of use for age-related hypogonadism; no testosterone product is approved for women, and medical groups recommend it mainly for menopausal low sexual desire.
Primary Research Supporting or Contradicting the Claim
In February 2025 the FDA removed boxed warning language on adverse cardiovascular outcomes (U.S. Food and Drug Administration, 2025), and in June 2026 requested further labeling updates (U.S. Food and Drug Administration, 2026b). The only evidence-based indication in women is hypoactive sexual desire disorder (Davis et al., 2019).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The regulatory chronology, approval status in women and the single evidence-based indication are reported accurately. The article includes expert concern about screening and fertility and does not attribute medical benefit to the policy.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug safety and availability. February 28, 2025.
Supporting excerpt: "removing language from the Boxed Warning related to an increased risk" - U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"